Shilpa Pharma Lifesciences Ltd, a wholly owned subsidiary of Shilpa Medicare Ltd, has successfully cleared a United States Food and Drug Administration (USFDA) inspection at its Unit-2 facility in Raichur, India, with zero observations. The inspection, conducted from March 10 to March 14, 2025, concluded without any Form 483 being issued, marking the second consecutive clean inspection at this site.
"This is to inform you that the United States Food and Drugs Administration (USFDA) has conducted an inspection at Unit-2 of Shilpa Pharma Lifesciences Limited, located at Raichur, from March 10-14, 2025. The inspection was closed with ZERO observations. This is the second consecutive ZERO 483 inspection from USFDA at this site," Shilpa Medicare stated in a regulatory filing.
Facility Capabilities and Significance
The Unit-2 API site, operational since March 21, 2008, is the company's second and largest API manufacturing facility, spanning 22 acres. With a capacity of 520 KL, the facility supports more than 250 customers across 25 APIs and is part of the company's CDMO (Contract Development and Manufacturing Organization) offerings.
Vishnukant C. Bhutada, Managing Director of Shilpa Medicare, expressed satisfaction with the outcome: "We are delighted that our Unit-2 API facility has passed its second consecutive FDA inspection with no observations. This achievement further reinforces our dedication to providing our customers with high-quality R&D, API, and finished dose manufacturing solutions."
The successful inspection demonstrates Shilpa Medicare's commitment to meeting and exceeding regulatory standards, showcasing the facility's state-of-the-art infrastructure, technical expertise, and high level of compliance through its systems, documentation, and records.
Broader Manufacturing Network
Unit-2 is part of Shilpa Medicare's broader network of seven facilities that encompass biologic substance manufacturing, fill-finish capabilities, and large-scale solid dose drug substance production. The successful FDA inspection ensures that the site will continue to support the commercial supply of oncological actives for U.S. patients.
Recent Regulatory History
This positive outcome follows a separate USFDA inspection at the company's Unit-1 facility in Raichur earlier this month. That inspection, conducted from March 3 to March 7, 2025, resulted in one procedural observation under Form 483. The company has committed to addressing this observation within the stipulated timeframe.
"The company will closely work with the agency and remain committed to address this observation comprehensively within stipulated time," Shilpa Medicare had stated regarding the Unit-1 inspection.
Market Response
On March 13, 2025, shares of Shilpa Medicare Ltd ended at ₹628.20 on the BSE, down by ₹17.10, or 2.65%. The market's response to the latest regulatory success remains to be seen.
The consecutive successful inspections strengthen Shilpa Medicare's position in the pharmaceutical manufacturing sector, particularly for its capabilities in producing high-quality APIs and supporting both generic and innovative drug development through its growing CDMO division.
